(AIM : SAR)

10 May 2013

Sareum Holdings plc

(“Sareum” or “the Company”)

Total Voting Rights

The Company announces that, pursuant to the requirements of the Disclosure and Transparency Rules, the total number of voting rights in respect of each class of share in issue and admitted to trading on AIM at the date of this announcement is as follows:

 

Total number of shares in issue

Total number of voting rights

Ordinary Shares of 0.025 pence each

1,521,538,263

1,521,538,263

 

 

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

For further information:

 

Sareum Holdings plc

Tim Mitchell

 

01223 497 700

Sanlam Securities UK (Nomad)

Simon Clements

 

020 7628 2200

Hybridan LLP (Broker)

Claire Noyce, Deepak Reddy

 

020 7947 4350

The Communications Portfolio Limited
(Media enquiries)

Ariane Comstive

Ariane.comstive@communications-portfolio.co.uk

 

020 7536 2028

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and auto-immune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum’s Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. The development candidate resulting from the collaboration increases the effectiveness of current cancer therapeutics in several in-vivo cancer models.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum’s drug discovery technology platform that has so far produced the Company’s Aurora+FLT3, Aurora+ALK VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange and trades under the symbol SAR.  For further information, please visit www.sareum.co.uk